Logo image of PTGX

PROTAGONIST THERAPEUTICS INC (PTGX) Stock Fundamental Analysis

NASDAQ:PTGX - US74366E1029 - Common Stock

57.48 USD
+1.44 (+2.57%)
Last: 8/22/2025, 8:00:02 PM
57.48 USD
0 (0%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

5

Overall PTGX gets a fundamental rating of 5 out of 10. We evaluated PTGX against 549 industry peers in the Biotechnology industry. While PTGX has a great health rating, its profitability is only average at the moment. PTGX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year PTGX was profitable.
PTGX had a positive operating cash flow in the past year.
PTGX had negative earnings in 4 of the past 5 years.
In the past 5 years PTGX reported 4 times negative operating cash flow.
PTGX Yearly Net Income VS EBIT VS OCF VS FCFPTGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

PTGX has a better Return On Assets (7.25%) than 91.80% of its industry peers.
PTGX's Return On Equity of 7.79% is amongst the best of the industry. PTGX outperforms 92.53% of its industry peers.
With an excellent Return On Invested Capital value of 2.78%, PTGX belongs to the best of the industry, outperforming 91.44% of the companies in the same industry.
Industry RankSector Rank
ROA 7.25%
ROE 7.79%
ROIC 2.78%
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
PTGX Yearly ROA, ROE, ROICPTGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Profit Margin of PTGX (24.88%) is better than 95.81% of its industry peers.
With an excellent Operating Margin value of 11.46%, PTGX belongs to the best of the industry, outperforming 93.08% of the companies in the same industry.
Industry RankSector Rank
OM 11.46%
PM (TTM) 24.88%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTGX Yearly Profit, Operating, Gross MarginsPTGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

PTGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PTGX has been increased compared to 1 year ago.
The number of shares outstanding for PTGX has been increased compared to 5 years ago.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PTGX Yearly Shares OutstandingPTGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PTGX Yearly Total Debt VS Total AssetsPTGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

PTGX has an Altman-Z score of 43.51. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PTGX (43.51) is better than 98.18% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 43.51
ROIC/WACC0.28
WACC9.76%
PTGX Yearly LT Debt VS Equity VS FCFPTGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 16.97 indicates that PTGX has no problem at all paying its short term obligations.
PTGX's Current ratio of 16.97 is amongst the best of the industry. PTGX outperforms 91.99% of its industry peers.
A Quick Ratio of 16.97 indicates that PTGX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 16.97, PTGX belongs to the best of the industry, outperforming 92.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.97
Quick Ratio 16.97
PTGX Yearly Current Assets VS Current LiabilitesPTGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for PTGX have decreased strongly by -73.28% in the last year.
Looking at the last year, PTGX shows a very negative growth in Revenue. The Revenue has decreased by -34.45% in the last year.
Measured over the past years, PTGX shows a very strong growth in Revenue. The Revenue has been growing by 352.10% on average per year.
EPS 1Y (TTM)-73.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)-34.45%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%33.09%

3.2 Future

The Earnings Per Share is expected to grow by 0.54% on average over the next years.
Based on estimates for the next years, PTGX will show a small growth in Revenue. The Revenue will grow by 7.60% on average per year.
EPS Next Y-148.06%
EPS Next 2Y-49.38%
EPS Next 3Y-31.39%
EPS Next 5Y0.54%
Revenue Next Year-82.14%
Revenue Next 2Y-28.65%
Revenue Next 3Y-13.61%
Revenue Next 5Y7.6%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PTGX Yearly Revenue VS EstimatesPTGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PTGX Yearly EPS VS EstimatesPTGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 82.11, which means the current valuation is very expensive for PTGX.
90.53% of the companies in the same industry are more expensive than PTGX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of PTGX to the average of the S&P500 Index (27.24), we can say PTGX is valued expensively.
The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 82.11
Fwd PE N/A
PTGX Price Earnings VS Forward Price EarningsPTGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaply inside the industry as 90.16% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 91.99% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 96.39
EV/EBITDA 101.29
PTGX Per share dataPTGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PTGX's earnings are expected to decrease with -31.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-49.38%
EPS Next 3Y-31.39%

More info and screens

0

5. Dividend

5.1 Amount

PTGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (8/22/2025, 8:00:02 PM)

After market: 57.48 0 (0%)

57.48

+1.44 (+2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners106.58%
Inst Owner Change6.33%
Ins Owners1.04%
Ins Owner Change-0.61%
Market Cap3.58B
Analysts84.44
Price Target69.27 (20.51%)
Short Float %9.53%
Short Ratio7.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.09%
Min EPS beat(2)6.78%
Max EPS beat(2)19.4%
EPS beat(4)4
Avg EPS beat(4)135.89%
Min EPS beat(4)6.78%
Max EPS beat(4)504.52%
EPS beat(8)8
Avg EPS beat(8)268.4%
EPS beat(12)10
Avg EPS beat(12)181.29%
EPS beat(16)13
Avg EPS beat(16)138.79%
Revenue beat(2)0
Avg Revenue beat(2)-14.45%
Min Revenue beat(2)-20.11%
Max Revenue beat(2)-8.8%
Revenue beat(4)2
Avg Revenue beat(4)81.15%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)232.24%
Revenue beat(8)4
Avg Revenue beat(8)41.38%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.01%
PT rev (3m)-2.21%
EPS NQ rev (1m)-6.42%
EPS NQ rev (3m)-13.36%
EPS NY rev (1m)-1.83%
EPS NY rev (3m)-4.23%
Revenue NQ rev (1m)-51.67%
Revenue NQ rev (3m)-43.04%
Revenue NY rev (1m)-29.53%
Revenue NY rev (3m)-26.79%
Valuation
Industry RankSector Rank
PE 82.11
Fwd PE N/A
P/S 17.09
P/FCF 96.39
P/OCF 90.43
P/B 5.35
P/tB 5.35
EV/EBITDA 101.29
EPS(TTM)0.7
EY1.22%
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)0.6
FCFY1.04%
OCF(TTM)0.64
OCFY1.11%
SpS3.36
BVpS10.74
TBVpS10.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.25%
ROE 7.79%
ROCE 3.51%
ROIC 2.78%
ROICexc 16.91%
ROICexgc 16.91%
OM 11.46%
PM (TTM) 24.88%
GM N/A
FCFM 17.74%
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 141.54%
Cap/Sales 1.17%
Interest Coverage 250
Cash Conversion 153.85%
Profit Quality 71.29%
Current Ratio 16.97
Quick Ratio 16.97
Altman-Z 43.51
F-Score4
WACC9.76%
ROIC/WACC0.28
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-73.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y-148.06%
EPS Next 2Y-49.38%
EPS Next 3Y-31.39%
EPS Next 5Y0.54%
Revenue 1Y (TTM)-34.45%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%33.09%
Revenue Next Year-82.14%
Revenue Next 2Y-28.65%
Revenue Next 3Y-13.61%
Revenue Next 5Y7.6%
EBIT growth 1Y-84.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-195.33%
EBIT Next 3Y-30.57%
EBIT Next 5YN/A
FCF growth 1Y131.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y133.67%
OCF growth 3YN/A
OCF growth 5YN/A